Loading page...
Loading page...
This round is closed. The next round and similar open calls are listed below. Synced from the EU Funding & Tenders Portal on 9 November 2026.
This call is closed. These open or upcoming calls fund the closest work.
Based on projects the EU funded on the same subject in this programme.
KEEPCARINGFuture Proofing Health- and Care Systems Safeguarding Health Care Workers in Hospital Settings
HORIZON-HLTH-2023-CARE-04-02 · 2024 · Official record ↗
CARE-IN-HEALTHCArdiovascularREsolution of INflammation to promote HEALTH
HORIZON-HLTH-2022-STAYHLTH-02-01 · 2023 · Official record ↗
SP-EUSocial Prescribing to promote and improve access to health and care services for people in vulnerable situations in Europe
HORIZON-HLTH-2024-CARE-04-04-two-stage · 2025 · Official record ↗
suHCOSystemic Sustainability Transition Solution for Health Care Organisations through PCP
HORIZON-HLTH-2024-CARE-14-01 · 2025 · Official record ↗
DYNAMOModelling and dynamic assessment of integrated health and care pathways enhancing response capacity of health systems
HORIZON-HLTH-2022-CARE-08-02 · 2023 · Official record ↗
ENACTEnvironmental Effect on Health Care and Wellbeing and Active Interventions
HORIZON-HLTH-2024-ENVHLTH-02-06-two-stage · 2025 · Official record ↗
EMPOWEREMpowering People living with NCDs and frOntline health Workers and levERaging digital health technology, to tackle the burden of chronic diseases in sub-Saharan Africa. (EMPOWER)
HORIZON-HLTH-2024-DISEASE-13-01 · 2025 · Official record ↗
COMFORTCOMputational Models FOR patienT stratification in urologic cancers – Creating robust and trustworthy multimodal AI for health care
HORIZON-HLTH-2022-TOOL-12-01-two-stage · 2023 · Official record ↗
Each one links to its EU funding record and the partners it works with: a starting list for building a consortium.
This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination “Tackling diseases and reducing disease burden”. To that end, proposals under this topic should aim to deliver results that are directed at, tailored towards and contributing to some of the following expected outcomes:
The Commission is a member of the Global Alliance for Chronic Diseases (GACD)[2]. The GACD specifically addresses NCDs and supports implementation research[3] to improve health outcomes. This topic is launched in concertation with the other GACD members (international funding agencies) and aligned with the 11th GACD call.
Besides health-related determinants, the burden of NCDs is also driven by structural and social inequities, population ageing, the effects of globalisation on marketing and trade, diet and activity, commercial and economic determinants of health, rapid urbanisation and climate change, factors over which a conventional healthcare-oriented system has little sway. There is a need for a comprehensive approach, involving sectors outside of health, to meet the global targets that governments have agreed upon to protect people from chronic NCDs. Tackling chronic NCDs most effectively therefore requires engagement and coordinated policy development within and across many government departments, including education, workplace, environment, social systems, housing, transportation, agriculture, food industry and nutrition, leisure and culture.
The aim of this topic is to fund implementation research focused on strategies to tackle the growing burden of NCDs through actions in sectors and settings outside the traditional health system[4] and its facilities (with or without the involvement of the healthcare system) to attain equitable health-related outcomes or influence health determinants for people living in LMICs, and/or underserved populations in HICs.
Proposals can focus on more than one setting and/or include cross-sectoral approaches, involving both health and non-health settings to expand efforts to reduce risks, prevent, manage and control NCDs. Safety is a major concern in non-health settings, and proposals should ensure any risks and safety considerations are addressed.
The choice of intervention(s)[5] and provision of existing evidence of the intervention’s effectiveness, cost-effectiveness, sustainability, scalability and potential for long-term health and other impacts should be justified (and in what context this evidence has been generated).
The majority of evidence-based interventions implemented outside of the health sector focus on prevention of NCDs: relatively few focus on strategies for management of these chronic conditions, and a limited number are implemented in LMIC contexts or underserved communities. Therefore, it may be important to undertake formative research as a part of the proposal to support readiness for implementation.
Applicants should explore the implementation of proposed intervention(s) for a selected study population(s) based in one or more LMICs, and/or underserved populations experiencing health disparities, including Indigenous populations, in HICs, considering the unique social, political, economic, and cultural context(s) in which the study will take place[6]. Applicants should justify why any adaptation will not compromise the known effectiveness of the selected intervention(s).
Proposals should address all the following implementation research activities[7]:
The study population may include the general population, people with one or more existing NCDs, those currently without NCDs, or a combination of both. Applicants may propose implementation research focused on interventions that are implemented at the individual, family, community (e.g. work or school), population, and/or structural level. With regard to NCDs, applicants are encouraged to explore any chronic non-communicable condition (or combination of conditions), including mental health disorders, substance use disorders, autoimmune conditions, musculoskeletal conditions, neurological disorders and sleep disorders and/or any risk factor (or combination of risk factors). Additionally, whenever relevant, applicants are also encouraged to take a life course approach, adapting interventions for particular life stages with the goal of promoting life-long health.
Proposals should use an appropriate implementation research design and frameworks[8], cluster Randomised Control Trials (cRCTs), before and after studies, and additional implementation science classifications of study designs (e.g. hybrid designs[9]), noting that applicants are not limited to any particular design.
Proposals are expected to generate evidence that is of direct relevance to policymakers, communities and practitioners. Proposed work should develop a strategy to include the relevant policymakers, local authorities, as well as other stakeholders such as community groups, or other individuals or organisations involved in the implementation of the intervention, with co-creation from the development of the proposal through to the knowledge translation phase. Project partners should be engaged from the beginning to contribute to the sustainability of the intervention after the end of project. Proposals should demonstrate sustainability of the strategy, beyond the lifespan of the project.
Poverty, discrimination based on sex, racial or ethnic origin[10], religion or belief, disability, age, and other inequities are directly associated with reduced potential for equitable access to quality care. Proposals should consider relevant determinants of health (e.g. social, structural, commercial, economic) and discuss their potential impact on the effective implementation of the intervention(s). If there is a focus on a particular population (e.g. gender, racial or ethnic origin[10], etc.), then the reason for this should be justified.
This topic requires the effective contribution of social sciences and humanities (SSH) disciplines and the involvement of SSH experts, institutions as well as the inclusion of relevant SSH expertise, in order to produce meaningful and significant effects enhancing the societal impact of the related research activities.
All projects funded under this topic are strongly encouraged to participate in networking and joint activities, including internationally, as appropriate. These activities could, for example, involve the participation in joint workshops, the Annual Scientific Meetings of the GACD, the exchange of knowledge, the development and adoption of best practices, or joint communication activities. Therefore, proposals are expected to include a budget for such activities and should consider covering the costs of any other potential joint activities without the prerequisite to detail concrete joint activities at this stage. The details of these joint activities will be defined during the grant agreement preparation phase.
Applicants should provide details of their clinical studies[12] in the dedicated annex using the template provided in the submission system. As proposals under this topic are expected to include clinical studies, the use of the template is strongly encouraged.
[1] As defined by the World Bank, https://www.worldbank.org
[2] https://www.gacd.org
[3] https://iris.who.int/bitstream/handle/10665/91758/9789241506212_eng.pdf
[4] In this context, non-healthcare settings can include for instance: workplaces; schools, universities and other education venues (including pre-schools, nursery, etc.); faith-based communities, places of worship and traditional healers; recreation and sports clubs, fitness centres, swimming pools; prisons; communities (geographic and/or of identity) and families; community pharmacies; theatres, community spaces; retirement homes and care homes; homeless shelters; markets, malls, commercial settings; barbers, hairdressers and beauty salons; urban environments, parks, transportation (the list is not exhaustive).
[5] Research proposals might explore implementation, outcomes and impact of context relevant strategies to implement evidence-based interventions or initiatives including (though not limited to):i) Non-health sector policy introduction, to tackle relevant social and/or structural determinants of NCDs; ii) Strategies to expand screening for NCDs and their risk factors in community, school, workplace, faith-based settings (e.g. Human Papillomavirus - HPV screening, blood pressure monitoring, blood sugar testing); ii) Partnered strategies to prevent NCDs in the community (e.g. educational campaigns, changes to school or work environments, promotion/delivery of healthy food choice and diet, opportunities for increased physical activity, strategies to support tobacco cessation and alcohol cessation); iv) Cost effective, patient centred treatment and management of NCDs in the community (e.g. mental health support, community medicine purchasing clubs, self-management groups); v) Non-health sector policy introduction e.g. environmental policy or practices (e.g. improvements to transport systems, public infrastructure) and the potential co-benefits on health; vi) Digital interventions e.g. for patient or care giver support, such as use of Artificial Intelligence for Patient support or to promote prevention messages on Chronic Disease Risk Factors).
[6] Focus on populations facing extreme vulnerabilities, such as individuals or communities living in informal settlements, post-disaster settings, or in situations of homelessness is encouraged (though not required).
[7] The following types of proposals are not in the scope of this topic: i) proposals with the primary aim of informing the development and/or selection of an intervention for a given context, where the implementation component will be explored in a future project (i.e. standalone feasibility projects);ii) epidemiological cohorts; iii) etiological work, mechanistic, or epidemiological research, unless an essential component of a focused study to develop implementation research approaches; iv) clinical trials, validation studies, or intervention efficacy studies for a new or established pharmacological agent or behavioural intervention.
[8] Examples of frameworks include (this list is not exclusive): i) Consolidated Framework for Implementation Research (CFIR); ii) the context enhanced (RE-AIM) Reach, Effectiveness, Adoption, Implementation, Maintenance); iii) Practical Robust Implementation and Sustainability Model (PRISM) frameworks; iv) Framework for Developing and Evaluating Complex Interventions (MRC & NIHR).
[9] https://pmc.ncbi.nlm.nih.gov/articles/PMC3731143 and https://pmc.ncbi.nlm.nih.gov/articles/PMC6779135
[10] The use of the term ‘racial or ethnic origin’ does not imply an acceptance of theories that attempt to determine the existence of separate human races.
[11] The use of the term ‘racial or ethnic origin’ does not imply an acceptance of theories that attempt to determine the existence of separate human races.
[12] Please note that the definition of clinical studies (see introduction to this Work Programme part) is broad and it is recommended that you review it thoroughly before submitting your application.
1. Admissibility Conditions, proposal page limit and layout
Admissibility conditions are described in Annex A and Annex E of the Horizon Europe Work Programme General Annexes.
Proposal page limits and layout are described in Part B of the Application Form available in the Submission System.
2. Eligible Countries
Eligible countries are described in Annex B of the Work Programme General Annexes.
A number of non-EU/non-Associated Countries that are not automatically eligible for funding have made specific provisions for making funding available for their participants in Horizon Europe projects. See the information in the Horizon Europe Programme Guide.
3. Other Eligibility Conditions
In recognition of the opening of the US National Institutes of Health’s programmes to European researchers, any legal entity established in the United States of America is eligible to receive Union funding.
If projects use satellite-based earth observation, positioning, navigation and/or related timing data and services, beneficiaries must make use of Copernicus and/or Galileo/EGNOS (other data and services may additionally be used).
Other eligibility conditions are described in Annex B of the Work Programme General Annexes.
4. Financial and operational capacity and exclusion
Financial and operational capacity and exclusion are described in Annex C of the Work Programme General Annexes.
5a. Evaluation and award: Award criteria, scoring and thresholds
Award criteria, scoring and thresholds are described in Annex D of the Work Programme General Annexes.
5b. Evaluation and award: Submission and evaluation processes
The thresholds for each criterion will be 4 (Excellence), 4 (Impact) and 4 (Implementation). The cumulative threshold will be 12.
Submission and evaluation processes are described in Annex F of the Work Programme General Annexes and the Online Manual.
5c. Evaluation and award: Indicative timeline for evaluation and grant agreement
Indicative timeline for evaluation and grant agreement are described in Annex F of the Work Programme General Annexes.
6. Legal and financial set-up of the grants
The granting authority may, up to 4 years after the end of the action, object to a transfer of ownership or to the exclusive licensing of results, as set out in the specific provision of Annex 5.
Eligible costs will take the form of a lump sum as defined in the Decision of 7 July 2021 authorising the use of lump sum contributions under the Horizon Europe Programme – the Framework Programme for Research and Innovation (2021-2027) – and in actions under the Research and Training Programme of the European Atomic Energy Community (2021-2025) [[This decision is available on the Funding and Tenders Portal, in the reference documents section for Horizon Europe, under ‘Simplified costs decisions’ or through this link: https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/guidance/ls-decision_he_en.pdf]].
Legal and financial set-up of the grants are described in Annex G of the Work Programme General Annexes.
Specific conditions are described in the specific topic of the Work Programme.
Application and evaluation forms and additional documents:
Application and evaluation form templates
Standard application form (HE RIA, IA) - the application form specific to this call is available in the Submission System
Standard evaluation form (HE RIA, IA) - will be used with the necessary adaptations
Guidance
HE Programme Guide
Model Grant Agreement (MGA)
Lump Sum MGA
Call-specific instructions 
Information on clinical studies (HE)
Detailed budget table (HE LS) 
Guidance: "Lump sums - what do I need to know?"
Additional documents
HE Main Work Programme 2026-2027 – 1. General Introduction
HE Main Work Programme 2026-2027 – 4. Health
HE Main Work Programme 2026-2027 – 15. General Annexes
HE Programme Guide
HE Framework Programme 2021/695
HE Specific Programme Decision 2021/764
EU Financial Regulation 2024/2509
Decision authorising the use of lump sum contributions under the Horizon Europe Programme
Rules for Legal Entity Validation, LEAR Appointment and Financial Capacity Assessment
EU Grants AGA — Annotated Model Grant Agreement
Funding & Tenders Portal Online Manual
Funding & Tenders Portal Terms and Conditions
Funding & Tenders Portal Privacy Statement
Applicants asked the EU 4 questions about this call and the EU published the answers. They clarify the call documents but do not replace them.
Yes, this is a Lump Sum topic, as stipulated in the specific conditions of the topic. To define and justify the Lump Sum, you need to provide a detailed budget table with cost estimations (downloadable as an Excel file form the online submission system). The estimations must be an approximation of your actual costs and meet the eligibility criteria of Horizon Europe.
In order to facilitate the evaluation of your proposal, you are encouraged to use the comments part of the detailed budget table and provide any details / explanations that are needed to better understand the specificities of your proposal. You are also advised to systematically justify any deviations in personnel costs.
Moreover, if your lump sum budget contains any cost items in cost category C and/or D, please make sure to justify these items in the comments part of the detailed budget table, as the proposal template has been simplified by removing this information from Part B and bringing it closer to the relevant budget items. Specifically, you must include justifications in the comments part of the detailed budget table if you are in any of the following situations:
Read it on the EU portal ↗Answered 6 Nov 2026
Please note that the definition of clinical studies, together with additional useful information can be found in the introduction of Health Cluster Work Programme part for 2026-2027.
Additionally, we would like to bring to your attention the fact that the World Health Organization (WHO) has published a “Guidance for best practices for clinical trials”. You are not required not follow this guidance, however we encourage you to do so.
Finally, we would also like to encourage you to consider the latest innovations and advances in the clinical trial design and research methods in order to evaluate promising interventions allowing shorter development timings.
Read it on the EU portal ↗Answered 28 Jun 2026
For the purpose of this call topic, an early career researcher typically refers to a PhD holder with 2-7 years of experience after completion of PhD award. The 7-year period may be extended to allow for career breaks related to circumstances such as parental leave, mandatory military or civil service, illness (own illness or care for close family members), medical internships or medical fellowship (applies to clinically active professionals).
Read it on the EU portal ↗Answered 15 Oct 2026
The Health Cluster Work Programme part for 2026-2027 includes a “right to object” condition for nearly all topics, giving the granting authority the right to object to a transfer of ownership or to the exclusive licensing of results, up to 4 years after the end of the action.
For applicants and beneficiaries, little is expected to change, as in previous years this condition had been part of the General Annexes, having legal force across all parts of Horizon Europe (including the Health Cluster topics). In practise, the granting authority may invoke the “right to object” under specific conditions, which so far has happened in very rare occasions over the many years of Horizon Europe.
More details below from Annex 5 of the General Model Grant Agreement:
Where the call conditions in Horizon Europe actions provide for the right to object to transfers or licensing, the granting authority may — up to four years after the end of the action — object to a transfer of ownership or the exclusive licensing of results, if:
the beneficiaries which generated the results have received funding under the grant
it is to a legal entity established in a non-EU country not associated with Horizon Europe, and
the granting authority considers that the transfer or licence is not in line with EU interests.
Beneficiaries that intend to transfer ownership or grant an exclusive licence must formally notify the granting authority before the intended transfer or licensing takes place and:
identify the specific results concerned
describe in detail the new owner or licensee and the planned or potential exploitation of the results, and
include a reasoned assessment of the likely impact of the transfer or licence on EU interests, in particular regarding competitiveness as well as consistency with ethical principles and security considerations.
The granting authority may request additional information.
If the granting authority decides to object to a transfer or exclusive licence, it must formally notify the beneficiary concerned within 60 days of receiving notification (or any additional information it has requested).
No transfer or licensing may take place in the following cases:
pending the granting authority decision, within the period set out above
if the granting authority objects
until the conditions are complied with, if the granting authority objection comes with conditions.
A beneficiary may formally notify a request to waive the right to object regarding intended transfers or grants to a specifically identified third party, if measures safeguarding EU interests are in place. If the granting authority agrees, it will formally notify the beneficiary concerned within 60 days of receiving notification (or any additional information requested).
Read it on the EU portal ↗Answered 28 Jun 2026
Confirm the current call documents and submission conditions with the funding authority.
View on EU portal ↗Source: EU Funding & Tenders Portal · synced 2026-11-09
A free account keeps your shortlist and sends deadline reminders. The EUACC connector brings this call, its FAQs, past winners and similar calls into Claude or ChatGPT, so you can check fit and draft with sources.